Vivos Therapeutics, Inc.VVOS決算レポート
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.
VVOS Q4 2025 Key Financial Metrics
売上高
$3.8M
粗利益
$3.0M
営業利益
$-6.4M
純利益
$-6.9M
粗利益率
78.1%
営業利益率
-166.8%
純利益率
-180.3%
前年比成長
3.4%
EPS
$-0.58
資金フロー
Vivos Therapeutics, Inc. Q4 2025 財務サマリー
Vivos Therapeutics, Inc. reported revenue of $3.8M (up 3.4% YoY) for Q4 2025, with a net profit of $-6.9M (down 143.8% YoY) (-180.3% margin). Cost of goods sold was $838.0K, operating expenses totaled $9.4M.
主要財務指標
| 総売上高 | $3.8M |
|---|---|
| 純利益 | $-6.9M |
| 粗利益率 | 78.1% |
| 営業利益率 | -166.8% |
| 報告期間 | Q4 2025 |
売上内訳
Vivos Therapeutics, Inc. Q4 2025 revenue of $3.8M breaks down across 2 segments, led by Services at $3.2M (84.5% of total).
| セグメント | 売上高 | 構成比 |
|---|---|---|
| Services | $3.2M | 84.5% |
| Products | $594.0K | 15.5% |
Vivos Therapeutics, Inc. セグメント別売上 — 四半期推移
Vivos Therapeutics, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Services and Products) has evolved quarter over quarter.
| セグメント | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Services | $3.2M | $4.6M | — | — |
| Products | $594.0K | — | $1.9M | $1.8M |
Vivos Therapeutics, Inc. 年度売上推移
Vivos Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $17.4M). Click any linked year to see what changed vs the prior 10-K.
Vivos Therapeutics, Inc. 四半期売上・純利益の履歴
Vivos Therapeutics, Inc. quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| 四半期 | 売上高 | 売上前年比 | 純利益 | 純利益率 |
|---|---|---|---|---|
| Q4 2025 | $3.8M | +3.4% | $-6.9M | -180.3% |
| Q3 2025 | $6.8M | +75.7% | $-5.4M | -79.6% |
| Q2 2025 | $3.8M | -5.8% | $-5.0M | -131.2% |
| Q1 2025 | $3.0M | -11.8% | $-3.9M | -128.1% |
| Q4 2024 | $3.7M | +13.9% | $-2.8M | -76.4% |
| Q3 2024 | $3.9M | +16.9% | $-2.6M | -67.8% |
| Q2 2024 | $4.1M | +19.4% | $-1.9M | -47.6% |
| Q1 2024 | $3.4M | -11.4% | $-3.8M | -110.1% |
損益計算書
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $3.4M | $4.1M | $3.9M | $3.7M | $3.0M | $3.8M | $6.8M | $3.8M |
| 前年比成長 | -11.4% | 19.4% | 16.9% | 13.9% | -11.8% | -5.8% | 75.7% | 3.4% |
貸借対照表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $11.8M | $15.8M | $15.3M | $15.3M | $11.3M | $26.0M | $25.6M | $25.2M |
| 総負債 | $11.2M | $9.5M | $7.7M | $7.3M | $6.9M | $21.4M | $23.1M | $26.7M |
| 株主資本 | $582000 | $6.3M | $7.7M | $8.0M | $4.4M | $4.6M | $2.5M | $-1.5M |
キャッシュフロー
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $-2.5M | $-3.0M | $-4.2M | $-2.9M | $-3.8M | $-3.5M | $-4.2M | $-3.8M |